Nuvectis Pharma (NASDAQ:NVCT) Issues Quarterly Earnings Results

Nuvectis Pharma (NASDAQ:NVCT) issued its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04, FiscalAI reports.

Nuvectis Pharma Trading Up 0.3%

NVCT traded up $0.03 during trading hours on Tuesday, hitting $8.92. The company’s stock had a trading volume of 49,342 shares, compared to its average volume of 60,196. The business’s 50-day moving average price is $8.48 and its 200-day moving average price is $7.76. Nuvectis Pharma has a 12 month low of $5.55 and a 12 month high of $11.15. The stock has a market cap of $246.68 million, a price-to-earnings ratio of -6.77 and a beta of -0.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuvectis Pharma in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On Nuvectis Pharma

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its position in Nuvectis Pharma by 3,398.9% in the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock worth $47,000 after purchasing an additional 6,084 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Nuvectis Pharma in the second quarter worth $53,000. Bank of America Corp DE increased its position in Nuvectis Pharma by 417.2% in the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock worth $64,000 after purchasing an additional 6,909 shares during the last quarter. Deutsche Bank AG increased its position in Nuvectis Pharma by 3,671.4% in the fourth quarter. Deutsche Bank AG now owns 12,672 shares of the company’s stock worth $96,000 after purchasing an additional 12,336 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new stake in Nuvectis Pharma in the second quarter worth $97,000. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.